DBV Technologies will participate in the next ACAAI 2024 congress

Châtillon, France, October 18, 2024

DBV Technologies will participate in the next ACAAI 2024 congress

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, 24 October 28th.^the2024 in Boston, Massachusetts.

This year’s meeting will feature a “Product Theater” in What defines an ideal peanut allergy treatment? During this panel discussion, Dr. Shahzad Mustafa, Edwin Kim, Julia Upton, and Food Allergy Research and Education (FAACT) CEO Eleanor Garrow-Holding will participate in a discussion about the characteristics of an ideal food allergy treatment. peanuts, focusing on the objectives of effectiveness, safety and practicality. Product Theater is set for Saturday, October 26th^thefrom 11:35 am to 1 pm EDT.

DBV also sponsors the 33rd^R^d Annual FIT Bowl, a game show-style competition that tests allergy, asthma and immunology knowledge of teams participating in training programs across the country. The competition will be held on Saturday, October 26^thefrom 5:45 pm to 7:45 pm EDT. Additionally, DBV is a Member of the ACAAI Benefactor Level Corporate Council in 2024. The Company will also have a stand at the ACAAI Exhibition Hall from Friday, October 25th.^the – Monday, October 28^the.

“We are delighted to be joining our food allergy colleagues again at ACAAI this year, especially after recently completing enrollment in VITESSE in children ages 4 to 7 years old,” he said Dr. Pharis Mohideen, Chief Medical Officer, DBV Technologies. “Our global collaboration has enabled us to reach this critical milestone. DBV continues to advance our regulatory progress with Viaskin^® peanut patch in children aged 1 to 3 years and 4 to 7 years. We look forward to opportunities at ACAAI to further discuss the unmet medical needs in peanut allergy and explore ways we can work together across the community to support the development of food allergy.”

DBV presentation:

Product Theater (non-CME)
“What Defines an Optimal Peanut Allergy Treatment?”. with the participation of Dr. FATO).

Performance date: Saturday, October 26th^the
Showtime: 11:35 a.m. to 1 p.m. EDT
Session/location: HCC, Level 2, Exhibition Halls C and D, Product Theater #2

The Viaskin® Peanut patch is the company’s lead product candidate, designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. An experimental, non-invasive, daily epicutaneous patch, the Viaskin Peanut patch seeks to deliver microgram amounts of peanut antigen to re-educate the immune system. The safety and effectiveness of the Viaskin Peanut patch have not yet been established by the U.S. Food and Drug Administration or the European Medicines Agency.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunological conditions with significant unmet medical needs. DBV is currently focused on investigating the use of its proprietary Viaskin® patch technology to treat food allergies, which are caused by a hypersensitivity immunological reaction and characterized by a range of symptoms ranging in severity from mild anaphylaxis to risk of life. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound into the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become insensitive to the allergen by taking advantage of the immune tolerance properties of the skin. DBV is committed to transforming care for people with food allergies. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut-allergic children (1 to 3 years of age) and toddlers (4 to 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s common shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one common share) are traded on the Nasdaq Capital Select Market (Ticker: DBVT).

For more information, visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Forward-looking statements
This press release may contain forward-looking statements and estimates, including statements about DBV’s financial condition, its cash flow forecast, the therapeutic potential of the Viaskin® Peanut patch and EPIT™, DBV’s anticipated clinical trial designs, regulatory efforts and DBV’s planned clinical trials including the timing and results of communications with regulatory agencies, the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected here are uncertainties generally associated with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute its measures of budgetary discipline. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set out in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”) . , DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including DBV’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, and future filings and reports prepared with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Except as required by applicable law, DBV TECHNOLOGIES assumes no obligation to update or revise the information contained in this press release.

Viaskin is a registered trademark and EPIT is a registered trademark of DBV Technologies.

Contact with investors
Katie Matthews
+1 (857) 529-2363
[email protected]

Media contact
Angela Marcucci
+1 646-842-2393
[email protected]